Literature DB >> 31026493

Genetic Analysis of Uveal Melanoma in 658 Patients Using the Cancer Genome Atlas Classification of Uveal Melanoma as A, B, C, and D.

Pornpattana Vichitvejpaisal1, Lauren A Dalvin2, Mehdi Mazloumi3, Kathryn G Ewens4, Arupa Ganguly4, Carol L Shields5.   

Abstract

PURPOSE: The Cancer Genome Atlas (TCGA) classification has been validated for uveal melanoma (UM) prognostication. We applied TCGA classification to UM biopsied using fine-needle aspiration biopsy (FNAB) to determine the predictability for metastasis and death.
DESIGN: Retrospective cohort study. PARTICIPANTS: Patients with UM treated with plaque radiotherapy at Wills Eye Hospital, Philadelphia, Pennsylvania, from October 1, 2008, through December 31, 2018, who completed genetic analysis of chromosomes 3 and 8 after FNAB.
METHODS: Tumors were classified as A, B, C, or D and were compared using the chi-square test, Fisher exact test, analysis of variance, and Kaplan-Meier analysis. MAIN OUTCOME MEASURES: Metastasis and death.
RESULTS: Six hundred fifty-eight UM patients were categorized accordingly as TCGA class A (n = 342 [52%]), B (n = 91 [14%]), C (n = 118 [18%]), and D (n = 107 [16%]). More advanced tumor classification revealed older mean patient age (56 vs. 53 vs. 60 vs. 63 years, respectively; P < 0.001), worse presenting visual acuity (20/20-20/50: 81% vs. 67% vs. 71% vs. 66%, respectively; P < 0.001), greater distance from the optic disc (3.5 vs. 4.9 vs. 5.7 vs. 5.3 mm, respectively; P < 0.001), larger tumor basal diameter (10.3 vs. 12.9 vs. 13.9 vs. 15.3 mm, respectively; P < 0.001), and greater tumor thickness (4.3 vs. 6.1 vs. 6.6 vs. 7.5 mm, respectively; P < 0.001). After mean follow-up (47.6 vs. 47.6 vs. 42.9 vs. 28.7 months, respectively; P < 0.001), more advanced TCGA class was associated with increased risk of metastasis (3% vs. 10% vs. 25% vs. 41%, respectively; P < 0.001) and death (1% vs. 0% vs. 3% vs. 9%, respectively; P < 0.001). Compared with class A, the 5-year hazard ratio for metastasis increased at 4.1 (B vs. A; P = 0.01), 10.1 (C vs. A; P < 0.001), and 30.0 (D vs. A; P < 0.001). The 5-year hazard ratio for death increased at 3.1 (C vs. A; P = 0.11) and 13.7 (D vs. A; P < 0.001) with no deaths in class B.
CONCLUSIONS: Grouping of UM using TCGA classification predicts the risk of melanoma-related metastasis and death.
Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31026493     DOI: 10.1016/j.ophtha.2019.04.027

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  10 in total

Review 1.  Is Tissue Still the Issue? The Promise of Liquid Biopsy in Uveal Melanoma.

Authors:  Daniël P de Bruyn; Aaron B Beasley; Robert M Verdijk; Natasha M van Poppelen; Dion Paridaens; Ronald O B de Keizer; Nicole C Naus; Elin S Gray; Annelies de Klein; Erwin Brosens; Emine Kiliç
Journal:  Biomedicines       Date:  2022-02-21

2.  Accuracy of The Cancer Genome Atlas Classification vs American Joint Committee on Cancer Classification for Prediction of Metastasis in Patients With Uveal Melanoma.

Authors:  Mehdi Mazloumi; Pornpattana Vichitvejpaisal; Lauren A Dalvin; Antonio Yaghy; Kathryn G Ewens; Arupa Ganguly; Carol L Shields
Journal:  JAMA Ophthalmol       Date:  2020-03-01       Impact factor: 7.389

Review 3.  Molecular Characteristics of Uveal Melanoma: Insights from the Cancer Genome Atlas (TCGA) Project.

Authors:  Mathieu F Bakhoum; Bita Esmaeli
Journal:  Cancers (Basel)       Date:  2019-07-27       Impact factor: 6.639

4.  SRSF2 Mutations in Uveal Melanoma: A Preference for In-Frame Deletions?

Authors:  Natasha M van Poppelen; Wojtek Drabarek; Kyra N Smit; Jolanda Vaarwater; Tom Brands; Dion Paridaens; Emine Kiliç; Annelies de Klein
Journal:  Cancers (Basel)       Date:  2019-08-17       Impact factor: 6.639

5.  Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy.

Authors:  Rui Fang; Heng Wang; Yang Li; Yue-Ming Liu; Wen-Bin Wei
Journal:  BMC Ophthalmol       Date:  2021-03-16       Impact factor: 2.209

6.  Analysis of Circulating Tumour Cells in Early-Stage Uveal Melanoma: Evaluation of Tumour Marker Expression to Increase Capture.

Authors:  Aaron B Beasley; Timothy W Isaacs; Tersia Vermeulen; James Freeman; Jean-Louis DeSousa; Riyaz Bhikoo; Doireann Hennessy; Anna Reid; Fred K Chen; Jacqueline Bentel; Daniel McKay; R Max Conway; Michelle R Pereira; Bob Mirzai; Leslie Calapre; Wendy N Erber; Melanie R Ziman; Elin S Gray
Journal:  Cancers (Basel)       Date:  2021-11-28       Impact factor: 6.639

7.  A Novel and Easy-to-Promote Prognostic Model for Patients With Uveal Melanoma.

Authors:  Han Yue; Binbin Xu; Jian Gao; Yingwen Bi; Kang Xue; Jie Guo; Rui Zhang; Hui Ren; Yifei Yuan; Jiang Qian
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

8.  Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours.

Authors:  Peter A Johansson; Kelly Brooks; Felicity Newell; Jane M Palmer; James S Wilmott; Antonia L Pritchard; Natasa Broit; Scott Wood; Matteo S Carlino; Conrad Leonard; Lambros T Koufariotis; Vaishnavi Nathan; Aaron B Beasley; Madeleine Howlie; Rebecca Dawson; Helen Rizos; Chris W Schmidt; Georgina V Long; Hayley Hamilton; Jens F Kiilgaard; Timothy Isaacs; Elin S Gray; Olivia J Rolfe; John J Park; Andrew Stark; Graham J Mann; Richard A Scolyer; John V Pearson; Nicolas van Baren; Nicola Waddell; Karin W Wadt; Lindsay A McGrath; Sunil K Warrier; William Glasson; Nicholas K Hayward
Journal:  Nat Commun       Date:  2020-05-15       Impact factor: 14.919

Review 9.  Prognostication of uveal melanoma is simple and highly predictive using The Cancer Genome Atlas (TCGA) classification: A review.

Authors:  Carol L Shields; Lauren A Dalvin; Pornpattana Vichitvejpaisal; Mehdi Mazloumi; Arupa Ganguly; Jerry A Shields
Journal:  Indian J Ophthalmol       Date:  2019-12       Impact factor: 1.848

10.  Fatty acid-binding protein 5 predicts poor prognosis in patients with uveal melanoma.

Authors:  Yue Xu; Wen-Hao Xu; Xiao-Long Yang; Hai-Liang Zhang; Xiao-Feng Zhang
Journal:  Oncol Lett       Date:  2020-01-14       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.